Management of dermatologic adverse events with apalutamide in prostate cancer

Video

“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.

In this video, Mario E. Lacouture, MD, discusses the background, findings, and takeaways of the Journal of Urology study, “Dermatologic adverse events in prostate cancer patients treated with androgen receptor inhibitor apalutamide.” Lacouture is a dermatologist at Memorial Sloan Kettering Cancer Center in New York, New York.

Related Videos
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Paul E. Dato, MD, an expert on prostate cancer
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Charles Parker, MD, answers a question during a Zoom video interview
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
© 2023 MJH Life Sciences

All rights reserved.